Last reviewed · How we verify

NCT05431608

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Active, enrolled Phase 1 Last updated 9 July 2025
What this trial tests

Phase 1 trial testing MCARH125 in Multiple Myeloma in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 June 2022
Primary endpoint
20 June 2026
20 June 2026

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationnon randomized
Designfactorial
Maskingnone
Primary purposetreatment
Enrollment15
Start date20 June 2022
Primary completion20 June 2026
Estimated completion20 June 2026
Sites7 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
    Zhang X, Zhang H, Lan H, Wu J, et al · · 2023 · cited 111× · PMID 36891310 · DOI 10.3389/fimmu.2023.1101495
  2. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
    Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, et al · · 2024 · cited 73× · PMID 38307865 · DOI 10.1038/s41408-023-00966-9
  3. Multiple myeloma: signaling pathways and targeted therapy.
    Lu Q, Yang D, Li H, Niu T, et al · · 2024 · cited 50× · PMID 38961036 · DOI 10.1186/s43556-024-00188-w
  4. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
    Mishra AK, Gupta A, Dagar G, Das D, et al · · 2023 · cited 29× · PMID 38006053 · DOI 10.3390/vaccines11111721
  5. Current use of CAR T cells to treat multiple myeloma.
    Firestone RS, Mailankody S. · · 2023 · cited 16× · PMID 38066841 · DOI 10.1182/hematology.2023000434
  6. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
    Xia J, Li Z, Xu K. · · 2023 · cited 11× · PMID 37277826 · DOI 10.1186/s13045-023-01461-1
  7. Updates on CAR T cell therapy in multiple myeloma.
    Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, et al · · 2024 · cited 10× · PMID 39261906 · DOI 10.1186/s40364-024-00634-5
  8. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
    Emde-Rajaratnam M, Beck S, Benes V, Salwender H, et al · · 2023 · cited 10× · PMID 38035078 · DOI 10.3389/fimmu.2023.1286700

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05431608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing